Pancreatic Cancer Research

ResearcherGuiyang Medical UniversityNo recent work listed

Jianxin Jiang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-7939-9082; OpenAlex author ID A5023548042. Sources: OpenAlex.

Their work

Papers
42 (first author 0, last author 25)
Trials
0
Grants
0
Labs led
2
Collaborators
55
Papers, trials and grants by year

2013: 1 paper · 2014: 3 papers · 2015: 7 papers · 2016: 5 papers · 2017: 3 papers · 2018: 2 papers · 2019: 2 papers · 2020: 2 papers · 2021: 10 papers · 2022: 4 papers · 2023: 3 papers

Papers 42

  1. KIF15 is essential for USP10-mediated PGK1 deubiquitination during the glycolysis of pancreatic cancer. Last author DOI 10.1038/s41419-023-05679-2↗
  2. USP33 promotes pancreatic cancer malignant phenotype through the regulation of TGFBR2/TGFβ signaling pathway. Last author DOI 10.1038/s41419-023-05871-4↗
  3. VSIG2 promotes malignant progression of pancreatic ductal adenocarcinoma by enhancing LAMTOR2-mediated mTOR activation. Last author DOI 10.1186/s12964-023-01209-x↗
  4. Exosome-derived FGD5-AS1 promotes tumor-associated macrophage M2 polarization-mediated pancreatic cancer cell proliferation and metastasis. Co-author DOI 10.1016/j.canlet.2022.215751↗
  5. LINC00941 promotes pancreatic cancer malignancy by interacting with ANXA2 and suppressing NEDD4L-mediated degradation of ANXA2. Last author DOI 10.1038/s41419-022-05172-2↗
  6. Dynamic regulation of KIF15 phosphorylation and acetylation promotes focal adhesions disassembly in pancreatic cancer. Last author DOI 10.1038/s41419-022-05338-y↗
  7. The role of lncRNA-mediated ceRNA regulatory networks in pancreatic cancer. Last author DOI 10.1038/s41420-022-01061-x↗
  8. YEATS2 is a target of HIF1α and promotes pancreatic cancer cell proliferation and migration. Last author DOI 10.1002/jcp.29995↗
  9. Long noncoding RNA LINC00941 promotes pancreatic cancer progression by competitively binding miR-335-5p to regulate ROCK1-mediated LIMK1/Cofilin-1 signaling. Last author DOI 10.1038/s41419-020-03316-w↗
  10. LncRNA CERS6-AS1 promotes proliferation and metastasis through the upregulation of YWHAG and activation of ERK signaling in pancreatic cancer. Last author DOI 10.1038/s41419-021-03921-3↗
  11. CircRNF13 Promotes the Malignant Progression of Pancreatic Cancer through Targeting miR-139-5p/IGF1R Axis. Last author DOI 10.1155/2021/6945046↗
  12. Circular RNA hsa_circ_0006117 Facilitates Pancreatic Cancer Progression by Regulating the miR-96-5p/KRAS/MAPK Signaling Pathway. Last author DOI 10.1155/2021/9213205↗
  13. [6]-Paradol suppresses proliferation and metastases of pancreatic cancer by decreasing EGFR and inactivating PI3K/AKT signaling. Last author DOI 10.1186/s12935-021-02118-0↗
  14. CircSEC24A upregulates TGFBR2 expression to accelerate pancreatic cancer proliferation and migration via sponging to miR-606. Last author DOI 10.1186/s12935-021-02392-y↗
  15. Comprehensive Analysis of Expression, Prognosis and Immune Infiltrates for Kinesin Superfamily Members in Human Pancreatic Adenocarcinoma Last author DOI 10.21203/rs.3.rs-550619/v1↗
  16. Hypoxia-Induced ZWINT Mediates Pancreatic Cancer Proliferation by Interacting With p53/p21. Last author DOI 10.3389/fcell.2021.682131↗
  17. MiR-489-3p Reduced Pancreatic Cancer Proliferation and Metastasis By Targeting PKM2 and LDHA Involving Glycolysis. Last author DOI 10.3389/fonc.2021.651535↗
  18. Upregulation of METTL14 mediates the elevation of PERP mRNA N6 adenosine methylation promoting the growth and metastasis of pancreatic cancer. Co-author DOI 10.1186/s12943-020-01249-8↗
  19. Nanomaterials: Applications in the diagnosis and treatment of pancreatic cancer. Last author DOI 10.4292/wjgpt.v11.i1.1↗
  20. MicroRNA-137 reduces stemness features of pancreatic cancer cells by targeting KLF12. Co-author DOI 10.1186/s13046-019-1105-3↗
  21. Long noncoding RNA 00976 promotes pancreatic cancer progression through OTUD7B by sponging miR-137 involving EGFR/MAPK pathway. Last author DOI 10.1186/s13046-019-1388-4↗
  22. HIF-3α Promotes Metastatic Phenotypes in Pancreatic Cancer by Transcriptional Regulation of the RhoC-ROCK1 Signaling Pathway. Last author DOI 10.1158/1541-7786.mcr-17-0256↗
  23. Combined inhibition of autophagy and Nrf2 signaling augments bortezomib-induced apoptosis by increasing ROS production and ER stress in pancreatic cancer cells. Co-author DOI 10.7150/ijbs.26776↗
  24. KIF15 promotes pancreatic cancer proliferation via the MEK-ERK signalling pathway. Last author DOI 10.1038/bjc.2017.165↗
  25. miR-138-5p suppresses autophagy in pancreatic cancer by targeting SIRT1. Last author DOI 10.18632/oncotarget.14360↗
  26. miR-1181 inhibits invasion and proliferation via STAT3 in pancreatic cancer. Last author DOI 10.3748/wjg.v23.i9.1594↗
  27. Par3 regulates invasion of pancreatic cancer cells via interaction with Tiam1. Co-author DOI 10.1007/s10238-015-0365-2↗
  28. TRIM37 promoted the growth and migration of the pancreatic cancer cells. Co-author DOI 10.1007/s13277-015-4078-7↗
  29. Tumor suppressor Fbxw7 antagonizes WNT signaling by targeting β-catenin for degradation in pancreatic cancer. Co-author DOI 10.1007/s13277-016-5217-5↗
  30. Simultaneous inhibition of the ubiquitin-proteasome system and autophagy enhances apoptosis induced by ER stress aggravators in human pancreatic cancer cells. Co-author DOI 10.1080/15548627.2016.1191722↗
  31. Blocking NF-κB Is Essential for the Immunotherapeutic Effect of Recombinant IL18 in Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-15-1144↗
  32. Expression and significance of HIF-1α and HIF-2α in pancreatic cancer. Last author DOI 10.1007/s11596-015-1521-3↗
  33. MicroRNA-138-5p regulates pancreatic cancer cell growth through targeting FOXC1. Co-author DOI 10.1007/s13402-014-0200-x↗
  34. MiR-1181 inhibits stem cell-like phenotypes and suppresses SOX2 and STAT3 in human pancreatic cancer. Co-author DOI 10.1016/j.canlet.2014.11.007↗
  35. Synergistic antitumor activity of withaferin A combined with oxaliplatin triggers reactive oxygen species-mediated inactivation of the PI3K/AKT pathway in huma… Co-author DOI 10.1016/j.canlet.2014.11.026↗
  36. Reduction of miR-29c enhances pancreatic cancer cell migration and stem cell-like phenotype. Co-author DOI 10.18632/oncotarget.3089↗
  37. Upregulation of miR-181c contributes to chemoresistance in pancreatic cancer by inactivating the Hippo signaling pathway. Last author DOI 10.18632/oncotarget.6298↗
  38. Upregulation of microRNA‑138‑5p inhibits pancreatic cancer cell migration and increases chemotherapy sensitivity. Last author DOI 10.3892/mmr.2015.4031↗
  39. KAP-1 is overexpressed and correlates with increased metastatic ability and tumorigenicity in pancreatic cancer. Co-author DOI 10.1007/s12032-014-0025-5↗
  40. MicroRNA-100 regulates pancreatic cancer cells growth and sensitivity to chemotherapy through targeting FGFR3. Co-author DOI 10.1007/s13277-014-2271-8↗
  41. microRNA-137 modulates pancreatic cancer cells tumor growth, invasion and sensitivity to chemotherapy. Co-author PMID 25550779↗
  42. Balanced Tiam1-rac1 and RhoA drives proliferation and invasion of pancreatic cancer cells. Co-author DOI 10.1158/1541-7786.mcr-12-0632↗

Closest collaborators

The 25 strongest of 55 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Xinyuan Liu · 10 shared papers, 2021–2023 · strength 1.80
  2. Jian Xu · 9 shared papers, 2021–2023 · strength 1.53
  3. Zhiwei He · 10 shared papers, 2019–2022 · strength 1.49
  4. Xueyi Jiang · 9 shared papers, 2021–2022 · strength 1.43
  5. Xingjun Guo · 16 shared papers, 2013–2020 · strength 1.17
  6. Yankun Chen · 7 shared papers, 2021–2022 · strength 1.07
  7. Jichuan Xu · 4 shared papers, 2022–2023 · strength 0.95
  8. Min Wang · 13 shared papers, 2013–2020 · strength 0.72
  9. Chao Yu · 11 shared papers, 2014–2019 · strength 0.70
  10. Gang Quan · 3 shared papers, 2022–2023 · strength 0.66
  11. Meiyuan Chen · 7 shared papers, 2015–2018 · strength 0.50
  12. Zhiwei He · 3 shared papers, 2021–2022 · strength 0.49
  13. Chengyi Sun · 7 shared papers, 2014–2019 · strength 0.47
  14. Jie Wang · 3 shared papers, 2017–2021 · strength 0.38
  15. Renyi Qin · 7 shared papers, 2013–2020 · strength 0.38
  16. Jie Wang · 2 shared papers, 2021–2022 · strength 0.35
  17. She Tian · 4 shared papers, 2016–2019 · strength 0.34
  18. Jie Wang · 2 shared papers, 2017–2023 · strength 0.32
  19. Peng Chen · 2 shared papers, 2021 · strength 0.28
  20. Tengxiang Chen · 2 shared papers, 2019–2021 · strength 0.28
  21. Zhirui Zeng · 2 shared papers, 2019–2021 · strength 0.28
  22. Shan Lei · 2 shared papers, 2019–2021 · strength 0.28
  23. Chengjian Shi · 5 shared papers, 2015–2020 · strength 0.26
  24. Ruizhi He · 4 shared papers, 2016–2020 · strength 0.25
  25. Chengyi Sun · 4 shared papers, 2014–2016 · strength 0.22

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.